Alaunos Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a report limited to 2023 Q4. Filed April 1, 2024.
Business context and reporting period
Alaunos was a clinical-stage oncology cell-therapy company developing engineered T-cell receptor therapies (TCR-T) for solid tumors. On August 14, 2023, it announced a strategic reprioritization, wound down its Phase 1/2 TCR-T trial, discontinued further clinical-program development, and reduced its workforce by approximately 95%. It is exploring strategic alternatives, including a merger, acquisition, asset sale, partnership, or financing, with Cantor Fitzgerald as strategic advisor. It is also evaluating potential in-licensing opportunities.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Collaboration revenue | $0.005 million | $2.922 million |
| Research and development expense | $16.279 million | $25.018 million |
| General and administrative expense | $12.219 million | $13.142 million |
| Operating loss | $34.267 million | $35.105 million |
| Net loss | $35.140 million | $37.730 million |
| Net loss per share, basic and diluted | $2.20 | $2.61 |
| Net cash used in operating activities | $30.142 million | $29.232 million |
Revenue was immaterial in 2023; the filing reports no product revenue. The prior-year collaboration revenue primarily included a $2.9 million Solasia milestone that did not recur. Profit margins are not meaningful given the company’s minimal revenue and continuing losses.
At December 31, 2023, cash and cash equivalents were $6.062 million, versus $39.058 million a year earlier; 2022 also included $13.938 million of restricted cash. Working capital was $6.3 million, down from $15.7 million. Total assets were $8.263 million and total liabilities were $1.956 million. The company had no debt outstanding at year-end after repaying its Silicon Valley Bank facility in May 2023. Cash declined by $46.934 million during 2023; investing activities provided $1.346 million, largely from equipment disposals, while financing activities used $18.138 million, primarily for debt repayment.
Material changes versus 2022
- Net loss narrowed by $2.590 million, while operating cash use increased by $0.910 million.
- Revenue fell by $2.917 million as the 2022 Solasia milestone did not recur.
- R&D expense declined 35% to $16.279 million, reflecting the clinical wind-down, lower headcount and facilities costs, an accrual adjustment, and a 2022 MD Anderson milestone payment that did not recur.
- 2023 included $1.269 million of restructuring costs and $4.803 million of impairment charges for property, equipment, and right-of-use assets following the reprioritization.
- The company terminated its NCI research agreement and patent license, closed its Houston cGMP facility, and terminated its operating leases. It returned its IL-12 assets to Precigen in April 2023.
Outlook, commentary, risks, and unusual items
- Liquidity and going concern: Management expected year-end cash to fund operations into the third quarter of 2024, but concluded that available resources would not fund planned operations for at least one year from the financial-statement issuance date. Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. There were no committed sources of additional capital.
- Strategic uncertainty: No transaction or definitive strategic course had been approved, and there is no assurance that a transaction will be identified or completed. The board may consider dissolution and liquidation if a transaction is not achieved; any distribution to stockholders would depend on timing and reserves for obligations and contingencies.
- Clinical data: Eight patients were treated in the halted Phase 1/2 trial. One patient had an objective partial response and six had stable disease; the reported overall response rate was 13% and disease control rate 87% among evaluable patients. No dose-limiting toxicities or ICANS were observed; CRS events were grades 1–3. All patients had progressed or withdrawn, and long-term follow-up continued for a subset. These early results are from a very small trial and do not establish efficacy.
- Licenses and assets: Termination of the NCI license may make restarting TCR-T development difficult. The company reported six pending patent-application families and no currently owned granted patents. It retains certain TCR rights under its amended Precigen license, subject to its terms.
- Nasdaq: The company regained compliance with the minimum bid-price rule after a 1-for-15 reverse stock split effective January 31, 2024. Nasdaq imposed a mandatory panel monitor through February 16, 2025; renewed noncompliance could lead to delisting.
- Litigation and restructuring: KBI Biopharma litigation was settled for $1.0 million in October 2023, with all claims dismissed. The company recorded $1.3 million in termination benefits, paid by year-end. As of March 1, 2024, it reported one full-time employee.
- Other governance and reporting notes: Management reported effective disclosure controls and internal control over financial reporting as of year-end. The auditor issued an unqualified opinion on the financial statements, highlighted going-concern doubt, and identified clinical and R&D accruals as a critical audit matter.
Important facts for investors to verify
- Current cash, monthly cash use, and whether financing or a strategic transaction has been secured since the filing.
- Whether management’s expected runway into Q3 2024 remains achievable and what actions are planned if it is not.
- Progress and terms of any strategic-alternative process, including potential liquidation and any related obligations or reserves.
- Status of the Nasdaq listing and compliance with the panel-monitor requirements through February 16, 2025.
- Rights retained after NCI license termination, the status of Precigen and MD Anderson agreements, and the practical value of the company’s TCR assets and pending patent applications.
- Final clinical-trial follow-up and any additional information that changes interpretation of the small, early-stage patient results.